ArticleCureus2025
Pattern Distribution and Utility of Reporting Anticellular Antibody Over Antinuclear Antibody: An Initial Report From the Immunofluorescence Laboratory of North Bengal Medical College and Hospital, West Bengal.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAntinuclear antibodies (ANA) are biomarkers used to diagnose, monitor, differentiate, and treat various systemic autoimmune rheumatic diseases (SARDs). The gold standard test for SARD screening involves using human epithelial cells (HEp-2) in an indirect immunofluorescence assay (IIFA) to detect ANA. However, diagnosing autoimmune disorders can be challenging when patients test ANA-negative but exhibit specific autoantibody patterns targeting the cytoplasm or mitotic spindle apparatus in the IIFA. To address this, the International Consensus on Antinuclear Antibody Patterns has proposed the term "anticellular antibodies" (ACA) to encompass various types of autoantibodies, including ANA. This study explores the rationale for shifting from reporting ANA to ACA in diagnosing SARDs. MATERIALS AND
methodsAn institutional observational study was conducted on 973 suspected and previously diagnosed patients in the Immunofluorescence Laboratory of the Department of Biochemistry of North Bengal Medical College and Hospital, West Bengal. IIFA using HEp-2 and monkey liver tissue (primate) substrates (EUROIMMUN, Lübeck, Germany) was performed after diluting patient serum samples at a ratio of 1:100.
resultsAmong the 973 study participants, 585 (60%) tested positive for ACA. Of these ACA-positive cases, 140 (24%) showed anticytoplasmic antibody positivity. This included 38 (6.5%) cases with isolated anticytoplasmic antibody positivity and 102 (17.4%) cases positive for both antinuclear and anticytoplasmic antibody patterns. Isolated anticytoplasmic antibodies were more prevalent among females of reproductive age, accounting for 22 (58%) of such cases.
conclusionsThe IIFA detected various autoantibodies when diagnosing SARDs. The presence of isolated anticytoplasmic antibodies in ANA-negative patients with autoimmune diseases indicates that the term ACA is more appropriate than ANA for diagnosing and reporting SARDs, as it may help reduce false-negative results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.